Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 11/20 | 0.56 |
| ▸ | ADRB3 | P13945 | 11/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 10/20 | 0.56 |
| ▸ | NPY1R | P25929 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7473303 | 0.88 | ADRB3 (0.58) | ADRB1ADRB3ADRB2LMNA | |
| SCHEMBL6951393 | 0.86 | ADRB1 (0.57) | ADRB1ADRB3ADRB2HRH1CCR3 | |
| SCHEMBL6944610 | 0.84 | ADRB3 (0.53) | ADRB1ADRB3ADRB2LMNAMEN1 | |
| SCHEMBL7469736 | 0.84 | ADRB3 (0.53) | ADRB1ADRB3ADRB2LMNA | |
| SCHEMBL6945509 | 0.83 | ADRB1 (0.58) | ADRB1ADRB3ADRB2LMNAMEN1 | |
| SCHEMBL6953354 | 0.83 | ADRB1 (0.55) | ADRB1ADRB3ADRB2NPY1RHRH1 | |
| SCHEMBL7469004 | 0.81 | ADRB3 (0.52) | ADRB1ADRB3ADRB2LMNAMEN1 | |
| SCHEMBL7473044 | 0.81 | ADRB3 (0.52) | ADRB1ADRB3ADRB2LMNAMEN1 | |
| SCHEMBL5204833 | 0.79 | ADRB1 (0.54) | ADRB1ADRB3ADRB2KMT2A | |
| SCHEMBL7836521 | 0.78 | LMNA (0.53) | ADRB1ADRB3ADRB2LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6649627-B1 | N-Substituted with 1- (pyrid-2-yl)-piperidine-4-yl radical; gastrointestinal and psychological disorder treatment; antidiabetic tocolytic, and antidepressant agents; irritable bowel syndrome, glaucoma and dysmenorrhoea | SANOFI-SYNTHELABO (FR) | 2003-11-18 | — | — | US | disclosed |
| EP-1087961-B1 | PHENOXYLPROPANOLAMINES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | SANOFI SYNTHELABO (FR) | 2002-08-14 | — | — | EP | disclosed |
| EP-1087961-A1 | PHENOXYLPROPANOLAMINES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | SANOFI-SYNTHELABO (FR) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065895-A1 | PHENOXYLPROPANOLAMINES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | SANOFI-SYNTHELABO (FR) | 1999-12-23 | — | — | WO | disclosed |